Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025Kensington, MD, USA and Munich/Martinsried, Germany, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
